Product Data Sheet

Cas No.:	888216-25-9	Cat. No:	PL04381
Product Name:	Ganetespib		
Product synonym:	3-(2,4-二羟基-5-异丙基苯基)-4-(1-甲基吲哚-5-基)-5-羟基-4H-1,2,4-三唑;3-(2,4-二羟基-5-异丙基苯基)-4-(1-甲基吲哚-5-基)-5-羟基-4H-1,2,4-噻唑;Ganetespib (STA-9090) 抑制剂		
Chemical name:	Ganetespib		
MF:	C20H20N4O3	FW:	364.3978
Purity:	≥99%	Batch No.:	-
Storage:			
Structural formula:			
λmax:	-	Formulation:	-
Solubility :			
SMILES :	O([H])C1C([H])=C(C(=C([H])C=1C([H])(C([H])([H])[H])C([H])([H])[H])C1=NN([H])C(N1C1C([H])=C([H])C2=C(C([H])=C([H])N2C([H])([H])[H])C=1[H])=O)O[H]		
InChI Code:	-		
InChI Key:			
WARNING This product is not for human or veterinary use.			

Product Description

Ganetespib (STA-9090) 是一种热休克蛋白 90 (HSP90) 抑制剂，在多种血液和实体肿瘤细胞系中表现出有效的细胞毒性。Ganetespib 通过抑制 HIF-1α 和 STAT3 对大肠癌具有抗血管生成作用。

生物活性	Ganetespib (STA-9090) is a heat shock protein 90 (HSP90) inhibitor which exhibits potent cytotoxicity in a wide variety of hematological and solid tumor cell lines. Ganetespib has antiangiogenic effects in colorectal cancer mediated through inhibition of HIF-1α and STAT3.
IC50 & Target[1][2]	HSP90

体外研究(In Vitro)	Ganetespib causes depletion of receptor tyrosine kinases, extinguishing of downstream signaling, inhibition of proliferation and induction of apoptosis with IC50 values ranging 2-30 nM in genomically-defined NSCLC cell lines. Ganetespib is also approximately 20-fold more potent in isogenic Ba/F3 pro-B cells rendered IL-3 independent by expression of EGFR and ERBB2 mutants. Ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematologic tumor cell lines, induces the degradation of known Hsp90 client proteins, displays superior potency to the ansamycin inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG). Ganetespib is a potent HSP90 inhibitor, and shown to kill canine tumor cell lines in vitro. Ganetespib possesses superior JAK/STAT inhibitory activity to both P6 and 17-AAG in terms of potency or duration of response in the HEL92.1.7 cells.
体内研究(In Vivo)	Ganetespib (125 mg/kg, i.v.) accumulates in tumors relative to normal tissues and displays greater in vivo efficacy than 17-AAG without increased toxicity and inhibits proliferation and induces apoptosis in parallel with EGFR depletion in NCI-H1975 xenografts. Ganetespib (100, 125, 150 mg/kg, i.v.) shows potent antitumor efficacy in solid and hematologic xenograft models of oncogene addiction, as evidenced by significant growth inhibition and/or regressions. has not independently confirmed the accuracy of these methods. They are for reference only.
包装储存	Powder -20°C 3 years；4°C 2 years
溶解度数据	In Vitro: DMSO : ≥ 100 mg/mL (274.42 mM)配制储备液